Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Clinical collaborative research of CBHI and Hallym University on the bone density increase by SAC in postmenopausal women


CBHI and Hallym University Collaborative Research

We hope SAC calcium becomes a breakthrough treatment for patients suffering from osteopenia or osteoporosis for which most calcium remedies in the market had proven largely ineffective

Calcium and Bone Health Institute (CBHI, http://www.cbhi.info), a nonprofit clinical research institute in Canada joined hands with Hallym University in South Korea for a collaborative clinical “evaluative study of SAC (Sigma Anti-Bonding Calcium Carbonate) treatment effects in women with postmenopausal osteopenia.” Professor Lee Sang-soo, the director of the Skeletal Aging Research Institute in Hallym University School of Medicine and Professor Ryu Ok-hyun will lead this research.

“We hope SAC calcium becomes a breakthrough treatment for patients suffering from osteopenia or osteoporosis for which most calcium remedies in the market had proven largely ineffective,” said Dr. Paul Lee, the president of CBHI. “This collaborative research will be a huge milestone, giving confidence and hope for people suffering from this devastating degenerative disease. The scientific framework of how SAC works is already laid out in the book titled ‘SAC for Calcium signaling’ (sold in Amazon.com) for those looking for a spoiler.”

SAC calcium employs sigma antibonding in calcium carbonate molecules to give its unique physical properties. When ingested, it will have our body absorb calcium in ionic form without the help of peptides and vitamin D, causing a slight elevation of ionic calcium level in our blood, which triggers hormonal responses that restore calcium homeostasis and robust bone-building processes, all-natural and safe processes without side effects.

The preliminary animal clinical study (2011) on induced osteoporosis in ovariectomized rats delivered very promising results. Also, a decade long volunteer-driven bone density case studies conducted by CBHI has already shown that SAC calcium improves bone health significantly and also alleviates symptoms of various calcium-related diseases. Already approved as a dietary supplement by Health Canada, SAC calcium is being marketed through participating physicians as a part of a more comprehensive clinical study with consenting patients and has shown encouraging results.

CBHI said that this collaborative study with Hallym University would prove the effects of SAC calcium on bone metabolism and may pave a way for subsequent studies to scientifically specify the mechanisms and pathways of healing to prevent and to treat over 150 calcium-related degenerative diseases. The study will predominantly focus on combating degenerative bone diseases such as osteoporosis, which is becoming a huge health challenge with extended life expectancy, especially for postmenopausal women. CBHI also recently entered into clinical collaborative research on multiple myeloma with the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute in early June 2020.

About CBHI

Calcium and Bone Health Institute (CBHI) is a nonprofit scientific research organization based in Canada. With the invention of novel SAC ionic calcium carbonate, its primary research focuses on the role of ionic calcium in treating over 150 calcium-related chronic degenerative diseases such as osteoporosis, arthritis, Alzheimer’s, metabolic disorders, etc. By conducting laboratory and clinical research, CBHI endeavors to find effective prevention and treatment options. CBHI collaborates with many research centers such as SFU, UBC, UC Davis, NSERC Canada, and BC Government to combine the research with fundamental sciences such as mathematics, chemistry, physics, and biology. It held the first International Sigma Anti-Bonding Calcium Symposium (ISACS) 2019 in Vancouver, Canada, to discuss and share the knowledge of the various measures to develop healthy bone and to prevent calcium-related diseases. This year, CBHI plans to hold ISACS in Manila, Philippines, which is not confirmed yet due to COVID-19 pandemic.

About the Skeletal Aging Research Institute in Hallym University School of Medicine

The Skeletal Aging Research Institute was founded to contribute to medical improvement with the leadership role in the medical research field of the artificial joint, senior skeleton, and arthritis, operating molecular biological, biological, medical engineering, and medical research system for aging-related musculoskeletal diseases. In the fundamental research field, it conducts research on the reaction of biomaterial in vivo, the exploration of bone-building accelerator, and the development of arthritis medicine to overcome osteolysis after the artificial joint procedure. In the medical research field, it contributes to the treatment of skeletal diseases worldwide through the research of joint surgery technique improvement, the fundamental and medical training for developing countries, and the support of medical treatment system improvement.

Share article on social media or email:

Life Sciences Industry Accelerates Growth and Navigates COVID-19 with eClinical Solutions’ ASCEND Clinical Data Services


“With ASCEND Clinical Data Services, we’re answering the call from emerging and mid-market sponsored trials for increased data access and control,” said Raj Indupuri, Co-Founder and CEO, eClinical Solutions.

With COVID-19 severely disrupting clinical studies, eClinical Solutions LLC, a leading global provider of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, has introduced ASCEND Clinical Data Services™ to help emerging and mid-market life sciences companies optimize their clinical data for rapid database lock and improved speed in drug submissions.

Clinical data management teams are increasingly outsourced, and sponsors are now working with an average of five data sources per trial. This has created data chaos and integration challenges, which are causing cycle time delays of 40 percent in the Last Patient Last Visit to Database Lock cycle time metric for sponsors using four or more data sources.* The COVID-19 pandemic has also been a catalyst for sponsors to move to more decentralized trial models that enable greater participation by patients from home and expanded centralized monitoring capabilities. ASCEND Clinical Data Services helps to address these challenges by combining leading clinical technology platforms, including eClinical Solutions’ elluminate® and the Medidata Rave Clinical Cloud, with clinical data management and biostatistical knowledge and expertise. This leads to more efficient data acquisition, standardization, data review, and analytics for improved decision making. Medidata is a Dassault Systèmes company.

“With ASCEND Clinical Data Services, we’re answering the call from emerging and mid-market sponsored trials for increased data access and control,” said Raj Indupuri, Co-Founder and CEO, eClinical Solutions. “Approvals for important treatments rely on data quality, and as data sources increase and clinical trials move towards virtualization, it is now critical for life sciences companies to access their data in real-time to achieve faster study cycle times and insights. Along with the ASCEND offering, our recent accreditation for Medidata RTSM reinforces our position as a true leader in providing agile, best-in-class clinical data services that are supported by cutting-edge technology platforms like elluminate and Medidata’s Clinical Cloud.”

“Since 2007, eClinical Solutions and Medidata have built a long-standing relationship driven by a shared mission of leveraging technology to improve the clinical research process,” said Katrina Rice, EVP, Professional Services, eClinical Solutions. “With seven accreditations across the Medidata Rave Clinical Cloud, eClinical Solutions and ASCEND Clinical Data Services are uniquely positioned to deliver increased value to Medidata Clinical Cloud clients through optimized study builds, data standardization and technology enabled data management and biostatistics services.”

For more on ASCEND Clinical Data Services, join our introductory webinar on Thursday, August 20: https://www.eclinicalsol.com/webinars/introduction-to-ascend-clinical-data-services/.

*The Tufts-eClinical Solutions Data Strategies & Transformation Study, 2019

About eClinical Solutions LLC

eClinical Solutions is a leading global provider of cloud-based enterprise software and software-driven clinical data services. The elluminate platform provides life sciences companies with greater control of their clinical trial data. elluminate software and data driven services have been used by more than 100 life sciences companies. For more information, visit http://www.eclinicalsol.com.

Share article on social media or email:

MGO CPA and ELLO Capital launch a multi-media Cannabis M & A Field Guide


“Where there was once a race for market share, now companies are looking to restructure or off-load underperforming assets in an effort to survive.”

MGO (Macias Gini & O’Connell LLP), one of the fastest-growing professional services firms in the US, and ELLO Capital, a boutique investment bank focused on cannabis, hemp and impacted industries, announced the launch of the “Cannabis M&A Field Guide.” This serialized multi-media project seeks to educate cannabis and hemp operators and investors on the evolving market conditions driving mergers and acquisitions, and provides first-person insight on best practices for strategy, structuring, valuation, and other topics behind successful M&A transactions.

“The drivers behind M&A deals in cannabis and hemp have changed drastically in the last 12 months,” said Hershel Gerson, CEO and Managing Director of ELLO Capital. “Where there was once a race for market share, now companies are looking to restructure or off-load underperforming assets in an effort to survive.”

The “Cannabis M&A Field Guide” will be built on a Thought Leadership series that addresses a wide variety of issues cannabis investors and operators face. Topics will include transaction structuring, valuations, tax impact, due diligence procedures, post-deal integration, and much more. The articles will be rolled out on a weekly basis, culminating in a PDF collection of all articles and additional content, which will be released in September 2020.

The effort will also include a webinar series addressing related topics through roundtables and other discussions with market leaders.

“The future of the cannabis and hemp industries will largely be shaped by how market leaders react to today’s difficult market conditions,” added Scott Hammon, leader of MGO’s Cannabis Practice. “Our team members are on the frontlines, guiding M&A transactions and implementing best practices. Our hope is to share our insight and help investors and operators navigate the M&A process and maximize value.”

The first two articles are available now at: http://www.mgocpa.com/cannabis-m-and-a

For further information or to speak to an MGO or ELLO Capital executive contact : Lorna Donohoe, ldonohoe@mgocpa.com or at +1 (310) 746-2174

Share article on social media or email:

CHESS Health Selected for Nationwide NIDA Study on Medication for Opioid Use Disorder


News Image

CHESS Health, the leading provider of technology for the addiction management lifecycle, announced today its eRecovery and eTherapy solutions will be included in a National Institutes of Health’s (NIH) study of medication for opioid use disorder (MOUD).

Funded through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, a trans-agency effort to find scientific solutions to the opioid crisis, the study will be managed by the National Institute on Drug Abuse (NIDA), part of NIH. The five-year clinical trial, organized through NIDA’s Clinical Trials Network, is a collaborative effort of researchers at NYU Grossman School of Medicine (John Rotrosen, MD), Harvard Medical School (Roger Weiss, MD), and the Columbia University Irving Medical Center (Edward V. Nunes, Jr., MD).

The main aims of the trial are to:

1. Test strategies to improve retention in treatment on medications for patients seeking treatment for opioid use disorder (MOUD).

2. Test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.

3. Develop predictive models of successful discontinuation of MOUD among patients who discontinue medication, based on patient characteristics, including duration of MOUD prior to discontinuation.

Patients stable on medication and who wish to taper and, ultimately, discontinue medication will be randomized to receive CHESS’ evidence-based Connections App plus medical management or medical management alone. They will also be randomized to receive different pharmacologic tapering strategies. The app will offer digital cognitive behavioral therapy (CBT), peer support through moderated discussion groups, access to recovery resources, high-risk location warnings, recovery progress tracking, and appointment and medication reminders. The study will measure the difference in successful discontinuation from medication without relapse to opioid use with and without the Connections App.

“This national study is incredibly important in testing strategies for medication adherence and discontinuation,” said Hans Morefield, chief executive officer of CHESS Health. “We are proud that our eRecovery and eTherapy solutions will not only help the patients and care teams involved in this study, but that the research into the impact of the Connections App will also help providers and payers prioritize the use of technology with treatment.”

“We’re developing and testing strategies to optimize treatment for patients who suffer from OUD and to help them achieve stable remission,” said John Rotrosen, MD, New York Node, NYU Grossman School of Medicine. “Technology is playing an ever-greater role in healthcare and is a key focus of our research. We are thrilled that CHESS Health has partnered with us to provide their innovative eRecovery app to our participants.”

About CHESS Health

CHESS Health is the developer of the leading, evidence-based telehealth platform supporting the entire addiction management life cycle. The platform facilitates digital handoffs for getting more patients into treatment (eIntervention); improves outcomes through digital CBT (eTherapy) and reduces relapse and supports long term recovery (eRecovery). For providers, the CHESS platform grows patient volume through more successful referrals, improves treatment delivery, and improves treatment outcomes, including reduced relapse. Health plans and governments also benefit from more individuals in treatment and better outcomes; with the CHESS platform, they also gain analytic insights into provider performance. CHESS Health has received recognition from the Substance Abuse and Mental Health Services Administration’s National Registry of Evidence-based Programs and Practices (NREPP), the Journal of Substance Abuse and the Surgeon General. For more information, visit http://www.chess.health.

Share article on social media or email:

EBSCO Information Services Announces Support for The UK Reproducibility Network


News Image

By working with organizations like EBSCO, we hope to move beyond simply the article to focusing on the actual research methods, code and data to improve reproducibility and research quality.

EBSCO Information Services (EBSCO) is joining the UK Reproducibility Network (UKRN) as an external stakeholder. In providing in-kind support to UKRN, EBSCO is furthering its goal of supporting open research and reproducibility by teaming up with an organization of researchers and research institutes dedicated to improving the quality of research.

As a provider of journals, e-books and a discovery service, EBSCO is well-known by researchers and the academic institutions that support them. Recent partnerships with protocols.io and Code Ocean have expanded EBSCO’s institutional reach allowing colleges and universities to further open research initiatives and make research methods, code and data available along with traditional research papers.

Part of EBSCO’s support for UKRN will include a series of workshops with protocols.io and Code Ocean addressing methods and protocol development, reproducibility and structuring research analytics. By bringing researchers together with companies that support research, EBSCO is able to balance its decades-long experience with academic research with its support for open research and research outputs and workflows.

Marcus Munafò, professor of biological psychology at the University of Bristol and programme lead within the MRC Integrative Epidemiology Unit, is on the UKRN Steering Committee. He says the UKRN’s goal is to elevate the quality of research being conducted. “We are looking at how researchers are incentivized and how that impacts what is being published. By working with organizations like EBSCO, we hope to move beyond simply the article to focusing on the actual research methods, code and data to improve reproducibility and research quality.”

EBSCO Information Services Vice President of Product Management and Researcher Workflows, Christopher Spalding says by working with UKRN, EBSCO is able to work directly with researchers to understand their needs and introduce them to resources like protocols.io and Code Ocean. “Improving the reproducibility of research and supporting open research are essential goals of both EBSCO and UKRN. protocols.io and Code Ocean are working to solve these problems, and EBSCO, as a UKRN external stakeholder, will both learn from and collaborate with researchers to benefit future research quality.”

About EBSCO Information Services

EBSCO Information Services (EBSCO) is the leading discovery service provider for libraries worldwide with more than 11,000 discovery customers in over 100 countries. EBSCO Discovery Service™ (EDS) provides each institution with a comprehensive, single search box for its entire collection, offering unparalleled relevance ranking quality and extensive customization. EBSCO is also the preeminent provider of online research content for libraries, including hundreds of research databases, historical archives, and clinical decisions tools serving millions of end users at tens of thousands of institutions. EBSCO is the leading provider of electronic journals & books for libraries, with subscription management for more than 360,000 serials, including more than 57,000 e-journals, as well as online access to more than 1,500,000 e-books. For more information, visit the EBSCO website at: http://www.ebsco.com. EBSCO Information Services is a division of EBSCO Industries, Inc., a family owned company since 1944.

For more information, please contact:

Kathleen McEvoy

Vice President of Communications

(800) 653-2726 x2594

kmcevoy@ebsco.com

Share article on social media or email:

The Stevie® Awards for Great Employers Final Deadline Extended through August 5


SAGE

All individuals and organizations worldwide—public and private, for-profit and non-profit, large and small—may submit nominations to the Stevie Awards for Great Employers.

“We’ve received so many requests for individual deadline extensions that we’ve decided to extend the deadline for everyone,” said Stevie Awards president Maggie Gallagher. The original final deadline was July 22. Gallagher emphasizes that no additional late fees will be charged for entries submitted

The Stevie® Awards, organizer of the Stevie Awards for Great Employers, announced today that the final entry deadline for the fifth annual competition has been extended to Wednesday, August 5.

The Stevie Awards for Great Employers honors the world’s best companies to work for and the HR teams and professionals, HR achievements, new products and services and suppliers that help to create and drive great workplaces.

“We’ve received so many requests for individual deadline extensions that we’ve decided to extend the deadline for everyone,” said Stevie Awards president Maggie Gallagher. The original final deadline was July 22. Gallagher emphasizes that no additional late fees will be charged for entries submitted through August 5, and late entries will not be penalized in the judging process.

All organizations now have three more weeks to prepare and submit their entries.

All individuals and organizations worldwide—public and private, for-profit and non-profit, large and small—may submit nominations to the Stevie Awards for Great Employers. The 2020 awards will honor achievements since the beginning of 2019. Entry details are available at http://www.StevieAwards.com/HR.

There are many new categories in 2020 for HR achievements including Achievement in Accessibility, Achievement in Leadership Development, Best Employee Value Proposition (EVP), Best Team Development Program, Best Use of Mobile Learning, and Most Innovative Learning and Development Program. Of the 16 HR Individual categories, 14 do not require an entry fee.

Several COVID-19 Response categories were recently added to the competition to recognize the positive ways that employers and HR professionals have responded to the pandemic. These categories have no entry fee.

Winners in the 31 industry-specific Employer of the Year categories will be determined by a unique blend of public votes and professional ratings. Public voting will take place from July 23–August 10.

The Stevie Awards for Great Employers will recognize achievement in many facets of the workplace. Categories include:

  • Employer of the Year
  • HR Achievements
  • HR Individual Awards
  • HR Team Categories
  • Solution Provider Awards
  • More than 50 New Product & Service Categories
  • COVID-19 response

More than 100 professionals worldwide, working on several juries, will determine the Stevie Award winners. Winners in the 2020 Stevie Awards for Great Employers will be honored at virtual awards ceremony on November 4.

About the Stevie® Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Middle East Stevie Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Share article on social media or email:

Robot That Prints New Skin Could Revolutionise Burns Treatment


The Inventia Skin team leading the skin regeneration revolution.

When we started Inventia Life Science, our vision was to create a technology platform with the potential to bring enormous benefit to human health. We are pleased to see how fast that vision is progressing alongside our fantastic collaborators – Dr Julio Ribeiro, CEO of Inventia Skin

A team including fast-growing Sydney start-up Inventia Life Science, world renowned skin surgeon and former Australian of the Year, Professor Fiona Wood, and leading bioprinting researcher, Professor Gordon Wallace, have received two major investments from the Australian Government to accelerate the development of a robotic device that prints a patient’s own skin cells directly onto a burn or wound.

The device, codenamed Ligō from the Latin ‘to bind’, could revolutionise the way we approach wound repair, and place Australia at the forefront of the burgeoning regenerative medicine industry.

Federal Health Minister Hon. Greg Hunt announced that the Government’s BioMedTech Horizons program, operated by MTPConnect, will inject funding to take the device into first-in-human clinical trials within two years. Separately, the team also received funding from the Medical Research Future Fund Stem Cell Therapies Mission to collaborate with stem cell expert Professor Pritinder Kaur from Curtin University, to use the Ligō device to deliver stem cell based products that could improve skin regeneration.

The skin, our body’s largest organ, is the first point of injury in accidents and some diseases. Damage it significantly and it will slowly heal and most likely leave a scar. However, throughout this process it will be open to infection while it tries to regenerate – a major problem in the body’s first protective barrier.

Inventia Skin’s Ligō robot prints tiny droplets containing the patient’s skin cells and biomaterials to speed up the regenerative process and create a new layer of skin where it has been damaged. The device uses patented technology developed in Australia by parent company Inventia Life Science and featured in its RASTRUM™ platform for lab-based medical research and drug discovery. In taking this core technology into the clinic in the Ligō robot, Inventia Skin is breaking new ground with some of Australia’s leaders in skin regeneration.

“When we started Inventia Life Science, our vision was to create a technology platform with the potential to bring enormous benefit to human health. We are pleased to see how fast that vision is progressing alongside our fantastic collaborators. This Federal Government support will definitely help us accelerate even faster,” says Dr. Julio Ribeiro, CEO and co-founder of Inventia.

The technology within Ligō enables the rapid and precise delivery of multiple cell types and advanced biomaterials to a wound, providing the potential to recreate functional and aesthetically normal skin. This can be achieved in a single procedure, reducing treatment cost and hospital stays, and minimising the risk of infection.

For one of its partners – Professor Fiona Wood, Director of Western Australia’s Burns Service – it’s not the first time that she has looked towards bioengineering to help her patients. Professor Wood pioneered the now clinically approved ‘spray-on skin’ technique to treat skin burns based on research beginning in 1993, and came to notice in 2002 at the time of the Bali Bombings. Combined with the expertise of Professor Gordon Wallace at the University of Wollongong, one of Australia’s most eminent researchers in bioprinting and biomaterials, Inventia Skin has a very bright future ahead.

“The combination of these grants is an excellent example of the way the Medical Research Future Fund is being applied across the continuum of translational research to commercialisation, leading to better patient outcomes,” says Professor Fiona Wood.

Learn more:

Further information on the BioMedTech Horizons Program is available here: https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/188-million-to-supercharge-digital-health-technologies

Contact Inventia Skin at info@inventiaskin.com

Twitter or LinkedIn @InventiaSkin

Australia: 1800 849 128

USA: +1 833 462 5959

Ireland: +353 818 370 035

Share article on social media or email:

Modere Ranks No. 3 of 50 Fastest-Growing Women-Led Companies


News Image

“As a global business, Modere has uniquely addressed a need in the health and wellness space. We are thrilled the company has been ranked third in this year’s 50 Fastest Growing Women-Led Companies, sponsored by American Express,” said Camille Burns, CEO, The Women Presidents’ Organization.

Modere, a global leader in the live-clean lifestyle space, today announced it has been ranked third on The Women Presidents’ Organization’s (WPO) annual list of the 50 Fastest Growing Women-Led Companies. Winners were announced at the WPO’s Annual Conference, “Reimagining Business”, which was presented online over July 22 and 23, 2020. Led by Chief Executive Officer Asma Ishaq, Modere celebrates its first year on the prestigious list.

“As a global business, Modere has uniquely addressed a need in the health and wellness space. We are thrilled the company has been ranked third in this year’s 50 Fastest Growing Women-Led Companies, sponsored by American Express,” said Camille Burns, Chief Executive Officer, the Women Presidents’ Organization.

Modere spearheaded today’s on-trend market for live-clean products when it launched its category-leading portfolio of clean-label beauty and personal care, health and wellness, and household products 30 years ago. “The company has demonstrated explosive growth under the leadership of CEO Asma Ishaq, and is a newcomer to the list,” added Burns. “We are inspired by her company’s success and particularly proud she is a member of WPO’s Zenith I Chapter.”

Evaluated for revenue performance during 2015-2019, during which time it experienced over 1500% growth in North America, the company is currently tracking at 75% growth in 2020 year to date compared to 2019 for the same time period.

“We attribute this honor to the many people whose extraordinary efforts have made this achievement possible,” remarked Ishaq. “I look forward to reaching our next growth goals in tandem with our loyal customers and exemplary employees and sales force around the world.”

The 50 Fastest list recognizes the advancement of women in business by honoring those women-led companies who have generated exponential growth. Nominees for this year’s list were ranked according to a sales growth formula combining percentage and absolute growth for revenues between 2015 and 2019.

“It is a privilege to be in the company of the talented women named to this list who have driven their companies’ remarkable accomplishments,” continued Ishaq. “We are indebted to the WPO for their support of women entrepreneurs and business leaders.”

About Modere

Modere (http://www.modere.com) offers a category-leading portfolio of live clean lifestyle essentials including beauty and personal care, health and wellness, and household products that are equal parts high-performing and scientifically designed. We believe modern health involves pure nutrition and a clean environment across all our product categories. Modere brings a holistic, live clean approach to well-being, and our products reflect a commitment to excellence and innovation with tested formulas proven around the globe. The recipient of multiple third-party validations, our line includes products that are US EPA Safer Choice-approved, EWG Verified™, NSF Certified and gray-water appropriate. The company is a proud supporter of Vitamin Angels®.

Share article on social media or email:

UgoVirtual Event Platform Enables Virtualization of AIDS2020, the “Woodstock of Global Science Conventions”


AIDS2020 Virtual Lobby

AIDS2020 Virtual Lobby

AIDS2020 is a critical event for the medical and scientific community worldwide, and it has been a true privilege to be a part of allowing the show to go on, even in the midst of the challenges presented by a global pandemic.

UgoVirtual, a comprehensive digital platform designed to meet the growing virtual event management and hosting needs of the international event sector, in partnership with leading global branding and event management agency MCI Group (MCI), announces the successful deployment of the 23rd International AIDS Conference (AIDS 2020: Virtual) which took place from July 6-10, 2020 on the UgoVirtual platform for virtualized conferences and hybrid events.

Dubbed by Science Magazine as “the Woodstock of global science conventions,” AIDS2020 is a biannual scientific and medical gathering dedicated to advancements in HIV/AIDS treatment and research. Traditionally held as a physical event, the 2020 conference was originally scheduled to be co-located in the cities of San Francisco and Oakland, California in the United States. Due to the worldwide outbreak and continued spread of the Coronavirus (COVID-19), organizers at the International AIDS Society (IAS), turned to the MCI Group in March to assist them with quickly pivoting the event online, in order to maintain continuity and momentum for a cure. After vetting multiple virtual event platform providers to ensure the necessary technology features, flexibility and bandwidth to enable an event of such a massive scope on a short timeline, MCI Group ultimately selected UgoVirtual as their strategic solution provider to enable the first virtual edition of the International AIDS Society Conference.

Featuring over 20,000 global attendees participating in more than 600 webinars, 12 prime sessions, 27 workshops, 50 symposia, 62 abstract sessions 10 pre-conference events and 70-plus satellite sessions, the massive virtual gathering was held on the originally scheduled dates and was deployed with a “follow the sun” schedule to accommodate multiple time zones. The agenda included live and pre-recorded sessions and presentations by leading scientists, health workers, policy specialists, community leaders, A-list celebrities, activists, government officials and even members of the British royal family. The information was presented on the backdrop of a visually stunning virtual environment designed by MCI Group, which was then digitized and securely delivered to the many thousands of global registered attendees on UgoVirtual’s robust and scalable virtual event platform.

The AIDS2020 Virtual conference enabled delegates to access and actively engage with the latest HIV science, advocacy and knowledge that is traditionally presented at the physical conference. In addition to a plethora of virtual sessions and community networking opportunities, the event featured a Global Village and Youth Programme that enabled participation by online audiences around the world. Educational content included presentations and appearances by such recognizable names as Sir Elton John, Dr. Deborah Birx, Prince Harry of the British royal family and Bill Gates of the Bill and Melinda Gates Foundation, as well as leading medical professionals, community leaders and individuals who have been affected by HIV and/or AIDS. The last day of the conference was devoted to providing information on containment and potential treatments for a more recent pandemic, COVID-19.

“AIDS2020 is a critical event for the medical and scientific community worldwide, and it has been a true privilege to be a part of allowing the show to go on, even in the midst of the challenges presented by a global pandemic,” said Diane Estner, strategic advisor for UgoVirtual. “The MCI Group team’s tireless work, dedication and skill in pivoting this landmark international event to a digital format was impressive and we are honored to have worked alongside them to make this a successful and productive experience for the many stakeholders around the world.”

“Due to not only the incredible size, scope and reach of AIDS2020, but to its critical importance to the global medical and scientific communities, it was essential that we provide a strategic and seamless solution to allow the transformation of its content to the digital realm,” said Shawn Pierce, President of Strategic Events, Meetings and Incentives at MCI Group. “UgoVirtual proved to be an ideal partner in this venture, providing the ideal blend of commitment, technology and expertise to bring our client’s vision to life virtually.”

In order to give scholarship delegates continued access to conference events and sessions, AIDS2020 Virtual content will remain online through July 30, 2020. Please visit http://www.aids2020.org for more information, or to learn more about UgoVirtual’s comprehensive virtual event platform, go to ugovirtual.com.

About UgoVirtual | UgoVirtual is a comprehensive digital platform that virtualizes tradeshows, conferences, association/corporate meetings, expositions, and other events to make them conveniently and securely accessible to online audiences around the world. As technologies like virtual reality, e-learning and web-conferencing have converged, UgoVirtual harnesses their combined power to resolve the pain points and challenges of event organizers, exhibitors and industry professionals, making it possible to BE EVERYWHERE. The brainchild of a group of technology industry veterans with over 80 years of combined experience, UgoVirtual leverages a proven digital platform that is currently utilized by many of the world’s leading enterprise organizations to virtualize events, provide on-demand content and allow online collaboration and learning environments. For more information, please visit https://ugovirtual.com/ and connect with us on Facebook, Twitter and LinkedIn.

About MCI | MCI is the global leader in engaging and activating audiences. Our business is founded on a simple human insight: When people come together, magic happens. Since 1987, we have been bringing people together through inspiring meetings, events, congresses and association or community management. MCI helps organisations harness the power of community by applying our strategic engagement and activation solutions to build unforgettable online and offline experiences that foster change, inspire, educate and enhance business performance. MCI is an independently owned company headquartered in Geneva, Switzerland, and boasts a global presence with 2,500+ professionals in 61 offices and 31 countries, who work with clients across Europe, the Americas, Asia-Pacific, India, and the Middle East. Visit us at http://www.mci-group.com or on LinkedIn, Twitter, https/Facebook, Instagram.

Share article on social media or email:



BPM+ Health Names Shane McNamee M.D. Chief Medical Information Officer


https://www.bpm-plus.org/

BPM+ Health, a community initiative to improve the quality and consistency of health care delivery, announced today that it has named Shane McNamee M.D. as its chief medical information officer (CMIO). A clinical solutions architect and board-certified physical medicine & rehabilitation (PM&R) physician, Dr. McNamee also serves as the CMIO for the health group of Perspecta, a BPM+ Health member company.

The BPM+ Health CMIO is responsible for establishing the unique clinical value proposition for BPM+ community and activities and assessing and driving community-wide health care automation priorities. In this role, Dr. McNamee will also foster collaborative relationships between existing health care standards bodies and industry and serve as a liaison between clinical and technical communities.

“Dr. McNamee’s background in rehab medicine gives him particular insight on the adverse impacts of failed care handoffs and transitions – some of the key problems we are trying to address in BPM+ Health,” said BPM+ Health Executive Director Ken Rubin. “In addition to having been an active member of BPM+ Health since day one, he is a tireless advocate in support of patient needs and quality improvement. Dr. McNamee has spent years engaged in the pragmatic application of health IT, especially across system and institutional boundaries, and is passionate and committed to seeing the advancement of solutions to address what has historically prevented effective and efficient care across the patient’s personal journey. I’m thrilled to see him elevated into the CMIO role.”

Dr. McNamee has proven sound judgment in leading and governing large, complex private sector corporations/organizations and has demonstrated performance in identifying and adopting technology innovations into operations for large public and private organizations. He is a polytrauma rehabilitation physician, specializing in the recovery of those with traumatic brain injury (TBI) and complex combat wounds. He is published in the fields of TBI, complex neurologic injuries, post-combat care and polytrauma. Dr. McNamee graduated as a Presidential Scholar from the Medical College of Ohio and completed residency in PM&R at the Virginia Commonwealth University.

About BPM+ Health

BPM+ Health is a community initiative to improve the quality and consistency of healthcare delivery. It will achieve this by applying business process modeling standards to clinical best practices, care pathways and workflows directly at the point of care. It is a cross-discipline group of professional organizations, clinical societies and healthcare providers working together to develop and pilot standards-driven healthcare process automation techniques to fully realize the benefits of Healthcare IT. BPM+ Health is a program of the Object Management Group® (OMG®). Visit https://www.bpm-plus.org/ for more information.

For a listing of all OMG trademarks, visit https://www.omg.org/legal/tm_list.htm. All other trademarks are the property of their respective owners.

Share article on social media or email: